Vice President Of Sales
CurrentI was recruited as the second commercial employee along with Chief Commercial Officer to launch the new US division and drive sales growth of Vegzelma, a new biosimilar oncology drug indicated for the treatment of: Metastatic Colorectal Cancer, First-Line Non-Squamous Non-Small Cell Lung Cancer, Recurrent Glioblastoma Metastatic Renal Cell Carcinoma, Persistent, Recurrent, or Metastatic Cervical Cancer, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. • Recruited and built a top-performing team including 2 National Directors, 2 Area Directors, and 12 Key Account Directors within two weeks.• Surpassed expectations by producing $78+ million in total sales from Q3 2023 product launch to YTD 2024. • Increased sales from Q3 to Q4 from 809 units to 23,241 units based on contract change from Q3 to Q4 of 2024`2800%.• Increased number of units sold 269% from 24,098 units in 2023 to 89,135 units through July 2024.• Drove sales volume by collaborating with Head of Commercial Training to develop/implement the highly successful Platinum Selling Model focused on pre-call planning, presentations, objection handling, closing skills, and use of the Insights Discovery Process.• Achieved a nearly 100% sales rep retention rate through leadership support and establishing incentive compensation plan to optimize sales rep engagement.• Collaborated with National Accounts to create clinic contracts with a lower off-invoice discount and higher rebates to maximize the Average Selling Price and by implementing a tiered contract based on performance with a loyalty component to encourage customers to strive for long-term incentives.• Worked with Sales Operations Team to develop detailed sales reports, providing valuable insights for strategic decision-making, sales force expansion, and overcoming competitor challenges.• Planned/launched key meetings and created the company deck and core visual aid, enhancing presentations and strengthening company messaging.
